XML 41 R12.htm IDEA: XBRL DOCUMENT
v3.21.1

Share Capital, Warrants and Options | 3 Months Ended
--- | ---
Mar. 31, 2021
SHARE CAPITAL, WARRANTS AND OPTIONS |
Share Capital, Warrants and Options |
| 7. | SHARE CAPITAL, WARRANTS AND OPTIONS
The authorized capital of the Company comprises an unlimited number of common shares without par value and 100,000,000 Series 1 convertible preferred shares without par value.
| a) | Common shares issued and outstanding
2021 During the three months period ended March 31, 2021, the Company issued 6,278,219 common shares and received $665,135 in proceeds from the exercise of 6,278,219 warrants. There were no warrants exercised during the three months period ended March 31, 2020. As at March 31, 2021, the Company has 116,111,867 common shares issued and outstanding, (March 31, 2020 - 88,690,791). 2020 On August 13, 2020, the Company closed the first tranche of its non-brokered private placement equity financing consisting of 15,481,077 units of the Company at a price of $0.07 per unit, for aggregate gross proceeds of $1,083,675. On August 31, 2020, the Company closed the second and final tranche of its non-brokered private placement equity financing consisting of 5,661,780 units of the Company at a price of $0.07 per unit, for aggregate gross proceeds of $396,325. Each unit consists of one common share in the capital of the Company and one transferable common share purchase warrant of the Company. Each warrant will entitle the holder to acquire one common share of the Company at an exercise price of $0.09 for a period of 24 months from its date of issuance. The warrants are subject to an acceleration clause such that if the closing market price of the common shares on the TSX-V is greater than $0.12 per common share for a period of 10 consecutive trading days at any time after the four-month anniversary of the closing of the placement, the Company may, at its option, accelerate the warrant expiry date to within 30 days. In connection with the non-brokered private financing, the Company incurred total share issuance costs of $124,222. The Company issued and aggregate of 588,154 common share purchase warrants. Each warrant will entitle the holder to acquire one common share of the Company at an exercise price of $0.09 for a period of 24 months from its date of issuance. The Company allocated a $716,055 fair value to the warrants issued in conjunction with the private placement and $18,547 to agent’s warrants. The fair value of warrants was determined using the Black-Scholes Option Pricing Model with the following assumptions; expected life of 2 years, expected dividend yield of 0%, a risk-free interest rate of 0.28% to 0.31% range and an expected volatility of 158% to 158.53% range. As at December 31, 2020 the Company had 109,833,648 common shares issued and outstanding.
| b) | Preferred shares issued and outstanding
As at March 31, 2021 and March 31, 2020, there are 590,931 series 1 preferred shares outstanding. The rights and restrictions of the preferred shares are as follows:
| i) | dividends shall be paid at the discretion of the directors;
| ii) | the holders of the preferred shares are not entitled to vote except at meetings of the holders of the preferred shares, where they are entitled to one vote for each preferred share held;
| iii) | the shares are convertible at any time after 6 months from the date of issuance, upon the holder serving the Company with 10 days written notice; and
| iv) | the number of the common shares to be received on conversion of the preferred shares is to be determined by dividing the conversion value of the share, $1 per share, by $9.00.
| c) | Warrants
A summary of common share purchase warrants activity during the three months period ended March 31, 2021 is as follows:
|  | March 31, 2021 |  |  | December 31, 2020 |
|  | Number Outstanding |  |  | Weighted Average Exercise Price ($) |  |  | Number Outstanding |  |  | Weighted Average Exercise Price ($) |
Outstanding, beginning of the period |  |  | 25,715,742 |  |  |  | 0.11 |  |  |  | 15,651,397 |  |  |  | 0.96 |
Issued |  |  | - |  |  |  | - |  |  |  | 21,731,011 |  |  |  | 0.09 |
Exercised |  |  | (6,278,219 | ) |  |  | 0.11 |  |  |  | - |  |  |  | - |
Cancelled / expired |  |  | - |  |  |  | - |  |  |  | (11,666,666 | ) |  |  | 1.20 |
Outstanding, end of the period |  |  | 19,437,523 |  |  |  | 0.12 |  |  |  | 25,715,742 |  |  |  | 0.11 |
At March 31, 2021, the Company had outstanding common share purchase warrants exercisable to acquire common shares of the Company as follows:
Warrants Outstanding |  |  | Expiry Date |  | Exercise Price ($) |  |  | Weighted Average remaining contractual life (years) |
| 3,359,133 |  |  | December 18, 2021 |  |  | 0.25 |  |  |  | 0.12 |
| 12,535,581 | 1 |  | August 13, 2022 |  |  | 0.09 |  |  |  | 0.88 |
| 3,542,809 | 1 |  | August 31, 2022 |  |  | 0.09 |  |  |  | 0.26 |
| 19,437,523 |  |  |  |  |  |  |  |  |  | 1.26 |
1 The warrants are subject to an acceleration clause such that if the volume-weighted average trading price of the Company’s common shares on the TSX-V exceeds $0.12 per common share for a period of 10 consecutive trading days at any date before the expiration date of such warrants, the Company may, at its option, accelerate the warrant expiry date to within 30 days. To March 31, 2021, the Company’s common shares have met the criterion for acceleration. The Company, however, has not accelerated the warrant expiry date.
| d) | Stock options
The Company adopted a Stock Option Plan (the “Plan”), providing the authority to grant options to directors, officers, employees and consultants enabling them to acquire up to 10% of the issued and outstanding common stock of the Company. Under the Plan, the exercise price of each option equals the market price or a discounted price of the Company’s stock as calculated on the date of grant. The options can be granted for a maximum term of 10 years. A summary of option activity under the Plan during the three months period ended March 31, 2021, is as follows:
|  | March 31, 2021 |  |  | December 31, 2020 |
|  | Number Outstanding |  |  | Weighted Average Exercise Price ($) |  |  | Number Outstanding |  |  | Weighted Average Exercise Price ($) |
Outstanding, beginning of the period |  |  | 7,978,725 |  |  |  | 0.17 |  |  |  | 2,130,550 |  |  |  | 1.51 |
Issued |  |  | 3,185,000 |  |  |  | 0.32 |  |  |  | 7,850,000 |  |  |  | 0.15 |
Cancelled / expired |  |  | (603,100 | ) |  |  | 0.33 |  |  |  | (2,001,825 | ) |  |  | 1.51 |
Outstanding, end of the period |  |  | 10,560,625 |  |  |  | 0.21 |  |  |  | 7,978,725 |  |  |  | 0.17 |
During the three months period ended March 31, 2021, the Company granted an aggregate total of 3,185,000 stock options to employees, directors and consultants with a maximum term of 5 years. All options vest immediately and are exercisable at $0.32 per share. The Company calculates the fair value of all stock options using the Black-Scholes Option Pricing Model. The fair value of options granted during the period ended March 31, 2021 amounted to $837,444 and was recorded as a share-based payment expense. During the three months period ended March 31, 2020, the Company granted 6,650,000 stock options to purchase common shares in the capital of the Company pursuant to the Company’s stock option plan. All of the options are exercisable for a period of five years at an exercise price of $0.16 per share. The fair value of options granted during the period ended March 31, 2020 amounted to $884,247 and was recorded as a share-based payment expense. The fair value of stock options granted and vested during the years ended March 31, 2021 was calculated using the following assumptions:
|  | March 31, 2021 |  |  | March 31, 2020 |
Expected dividend yield |  |  | 0 | % |  |  | 0 | %
Expected share price volatility |  |  | 127.83 | % |  |  | 121.55 | %
Risk free interest rate |  |  | 0.93 | % |  |  | 1.21 | %
Expected life of options |  |  | 5 years |  |  |  | 5 years |
Details of options outstanding as at March 31, 2021 are as follows:
Options Outstanding |  |  | Options Exercisable |  |  | Expiry Date |  | Exercise Price ($) |  |  | Weighted average remaining contractual life (years) |
| 40,625 |  |  |  | 40,625 |  |  | February 21, 2022 |  |  | 1.20 |  |  |  | 0.00 |
| 35,000 |  |  |  | 35,000 |  |  | February 28, 2023 |  |  | 1.20 |  |  |  | 0.01 |
| 6,100,000 |  |  |  | 6,100,000 |  |  | February 24, 2025 |  |  | 0.16 |  |  |  | 2.27 |
| 1,200,000 |  |  |  | 1,200,000 |  |  | August 19, 2025 |  |  | 0.09 |  |  |  | 0.50 |
| 3,185,000 |  |  |  | 3,185,000 |  |  | February 25, 2026 |  |  | 0.32 |  |  |  | 1.49 |
| 10,560,625 |  |  |  | 10,560,625 |  |  |  |  |  |  |  |  |  | 4.27 |
| e) | Reserve
The reserve records items recognized as stock-based compensation expense and other share-based payments until such time that the stock options or warrants are exercised, at which time the corresponding amount will be transferred to share capital. Amounts recorded for forfeited or expired unexercised options and warrants are transferred to deficit. During the three months period ended March 31, 2021, the Company transferred $97,953 (March 31, 2020 - $199,971) to deficit for expired options and transferred $242,901 (March 31, 2020 - $Nil) to common share capital for exercised warrants. During the three months period year ended March 31, 2021, the Company recorded $837,444 of share-based payments to reserves (March 31, 2020 - $884,247).

X
- References No definition available. + Details
Name: | WSCRF_DisclosureOfShareCapitalWarrantsAndOptionsAbstract
Namespace Prefix: | WSCRF_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of share capital, warrants and options, explanatory. + References No definition available. + Details
Name: | WSCRF_DisclosureOfShareCapitalWarrantsAndOptionsExplanatory
Namespace Prefix: | WSCRF_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration